Craft

Pharmosa Biopharm

Stock Price

NT$61

2024-10-29

Market Capitalization

NT$7.8 B

2024-10-29

Revenue

NT$67.3 M

FY, 2025

Pharmosa Biopharm Summary

Company Summary

Overview
Pharmosa Biopharm (PBI) is a biotechnology company that focuses on developing drugs. Its products include inhalation formulations and drug-device combinations for pulmonary vascular, peripheral vascular, and other diseases.
Type
Public
Status
Active
Founded
2000
HQ
TW | view all locations
Website
https://www.pharmosa.com.tw/
Cybersecurity rating
Sectors

LocationsView all

1 location detected

  • Taipei City HQ

    Taiwan

    3f, No. 3, Sanchong Rd, Nangang District

Pharmosa Biopharm Financials

Summary Financials

Revenue (FY, 2025)
NT$67.3M
Gross profit (FY, 2025)
NT$44.5M
Net income (FY, 2025)
(NT$383.8M)
Cash (FY, 2025)
NT$631.2M
EBIT (FY, 2025)
(NT$403.7M)
Enterprise value
$7.2B

Footer menu